WO2008108257A1 - 癌抗原特異的t細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用 - Google Patents
癌抗原特異的t細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用 Download PDFInfo
- Publication number
- WO2008108257A1 WO2008108257A1 PCT/JP2008/053469 JP2008053469W WO2008108257A1 WO 2008108257 A1 WO2008108257 A1 WO 2008108257A1 JP 2008053469 W JP2008053469 W JP 2008053469W WO 2008108257 A1 WO2008108257 A1 WO 2008108257A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- cell receptor
- specific
- cancer antigen
- peptide encoded
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Abstract
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08720964A EP2116596A4 (en) | 2007-03-05 | 2008-02-28 | L-CELL RECEPTOR GENE SPECIFIC TO A CANCER ANTIGEN, PEPTIDE CODED BY THE GENE AND THEIR USE |
MX2014010820A MX343633B (es) | 2007-03-05 | 2008-02-28 | Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos. |
JP2009502541A JP5808079B2 (ja) | 2007-03-05 | 2008-02-28 | 癌抗原特異的t細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用 |
CA002679045A CA2679045A1 (en) | 2007-03-05 | 2008-02-28 | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
AU2008222061A AU2008222061B2 (en) | 2007-03-05 | 2008-02-28 | Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them |
KR1020157023123A KR101773690B1 (ko) | 2007-03-05 | 2008-02-28 | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
CN2008800134367A CN101668853B (zh) | 2007-03-05 | 2008-02-28 | 癌抗原特异性t细胞受体基因、由该基因编码的肽及其使用 |
KR1020177023678A KR101900639B1 (ko) | 2007-03-05 | 2008-02-28 | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
EP19150097.4A EP3492590A3 (en) | 2007-03-05 | 2008-02-28 | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
KR1020097018554A KR101669279B1 (ko) | 2007-03-05 | 2008-02-28 | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
BRPI0808341-0A2A BRPI0808341A2 (pt) | 2007-03-05 | 2008-02-28 | Gene do receptor de célula t específico para antígeno de câncer, peptídeo codificado pelo gene e uso dos mesmos |
US12/529,701 US10093977B2 (en) | 2007-03-05 | 2008-02-28 | Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them |
MX2009009589A MX2009009589A (es) | 2007-03-05 | 2008-02-28 | Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos. |
US14/184,979 US10669584B2 (en) | 2007-03-05 | 2014-02-20 | Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them |
US14/184,816 US20140315758A1 (en) | 2007-03-05 | 2014-02-20 | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
US16/857,005 US20210017599A1 (en) | 2007-03-05 | 2020-04-23 | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-054215 | 2007-03-05 | ||
JP2007054215 | 2007-03-05 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/529,701 A-371-Of-International US10093977B2 (en) | 2007-03-05 | 2008-02-28 | Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them |
US14/184,816 Continuation US20140315758A1 (en) | 2007-03-05 | 2014-02-20 | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
US14/184,979 Division US10669584B2 (en) | 2007-03-05 | 2014-02-20 | Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008108257A1 true WO2008108257A1 (ja) | 2008-09-12 |
Family
ID=39738141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/053469 WO2008108257A1 (ja) | 2007-03-05 | 2008-02-28 | 癌抗原特異的t細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用 |
Country Status (11)
Country | Link |
---|---|
US (4) | US10093977B2 (ja) |
EP (4) | EP2116596A4 (ja) |
JP (3) | JP5808079B2 (ja) |
KR (3) | KR101669279B1 (ja) |
CN (2) | CN101668853B (ja) |
AU (1) | AU2008222061B2 (ja) |
BR (1) | BRPI0808341A2 (ja) |
CA (1) | CA2679045A1 (ja) |
MX (2) | MX343633B (ja) |
TW (2) | TWI615470B (ja) |
WO (1) | WO2008108257A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009059804A2 (en) * | 2007-11-05 | 2009-05-14 | Medinnova As | T-cell receptor peptides specific for part of cd20, uses thereof, and methods of preparing cytotoxic t-cells |
WO2013002086A1 (ja) | 2011-06-28 | 2013-01-03 | 株式会社癌免疫研究所 | ペプチド癌抗原特異的t細胞のレセプター遺伝子 |
WO2014007266A1 (ja) * | 2012-07-02 | 2014-01-09 | 大日本住友製薬株式会社 | 癌抗原ペプチド経皮剤 |
WO2014042226A1 (ja) * | 2012-09-12 | 2014-03-20 | 株式会社癌免疫研究所 | 抗原特異的ヘルパーt細胞レセプター遺伝子 |
JP2014143982A (ja) * | 2013-01-30 | 2014-08-14 | Igaku Seibutsugaku Kenkyusho:Kk | T細胞レセプターおよびその利用 |
US9663563B2 (en) | 2013-03-12 | 2017-05-30 | Sumitomo Dainippon Pharma Co., Ltd. | Aqueous liquid composition |
US10500257B2 (en) | 2003-06-27 | 2019-12-10 | International Institute Of Cancer Immunology, Inc. | Method of selecting WT1 vaccine adaptive patient |
WO2020127357A1 (en) * | 2018-12-18 | 2020-06-25 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
WO2021060343A1 (ja) * | 2019-09-24 | 2021-04-01 | オンコセラピー・サイエンス株式会社 | Urlc10由来ペプチドまたはdepdc1由来ペプチドを認識するヒトt細胞が発現するt細胞受容体 |
WO2021236548A1 (en) * | 2020-05-18 | 2021-11-25 | Board Of Regents, The University Of Texas System | Engineered t cell receptors and methods of use |
WO2022012280A1 (zh) * | 2020-07-11 | 2022-01-20 | 成都益安博生物技术有限公司 | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080070835A1 (en) | 2003-11-05 | 2008-03-20 | International Institute Of Cancer Immunology, Inc | Hla-Dr-Binding Antigen Peptide Derived From Wt1 |
PT2119778E (pt) | 2007-02-27 | 2016-02-15 | Int Inst Cancer Immunology Inc | Método para ativação de célula t auxiliar e composição para utilização no método |
NZ582822A (en) * | 2007-07-27 | 2012-06-29 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
AR083295A1 (es) | 2010-10-05 | 2013-02-13 | Univ Osaka | Metodo para activar celulas t auxiliares |
US9539299B2 (en) | 2011-10-27 | 2017-01-10 | International Institute Of Cancer Immunology, Inc. | Combination therapy with WT1 peptide vaccine and temozolomide |
WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
US20150133342A1 (en) * | 2012-05-04 | 2015-05-14 | Nuclea Biotechnologies, Inc. | Mrm-ms signature assay |
GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
WO2014098012A1 (ja) | 2012-12-17 | 2014-06-26 | 大塚製薬株式会社 | ヘルパーt細胞の活性化方法 |
CN106170297A (zh) * | 2013-09-20 | 2016-11-30 | 纪念斯隆-凯特琳癌症中心 | 用于wt‑1‑阳性疾病的组合/辅助疗法 |
US11390921B2 (en) | 2014-04-01 | 2022-07-19 | Adaptive Biotechnologies Corporation | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) |
CA2945393C (en) * | 2014-04-24 | 2021-03-23 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
EP3067366A1 (en) * | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
TWI726920B (zh) * | 2015-10-14 | 2021-05-11 | 耶魯大學 | 基因體規模的t細胞活性陣列、其製造方法、其用於辨識免疫調節因子的方法及其用途 |
CA3042890A1 (en) | 2016-11-14 | 2018-05-17 | Fred Hutchinson Cancer Research Center | High affinity merkel cell polyomavirus t antigen-specific tcrs and uses thereof |
BR112019018863A8 (pt) * | 2017-03-15 | 2023-05-02 | Hutchinson Fred Cancer Res | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos |
WO2018231958A1 (en) * | 2017-06-13 | 2018-12-20 | Adaptive Biotechnologies Corp. | Determining wt-1 specific t cells and wt-1 specific t cell receptors (tcrs) |
DE102017114737A1 (de) * | 2017-06-30 | 2019-01-03 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
US11919937B2 (en) | 2018-01-09 | 2024-03-05 | Board Of Regents, The University Of Texas System | T cell receptors for immunotherapy |
US20210252057A1 (en) * | 2018-05-16 | 2021-08-19 | Fred Hutchinson Cancer Research Center | Merkel cell polyomavirus t antigen-specific tcrs and uses thereof |
US20220340638A1 (en) * | 2018-07-12 | 2022-10-27 | Bgi Shenzhen | Mart-1(27-35) epitope-specific t cell receptor |
CN111116754A (zh) * | 2018-10-30 | 2020-05-08 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性tcr及其应用 |
GB201817821D0 (en) * | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
JP2022506781A (ja) * | 2018-11-09 | 2022-01-17 | フレッド ハッチンソン キャンサー リサーチ センター | メソテリンを標的とする免疫療法 |
US20220251167A1 (en) * | 2019-06-21 | 2022-08-11 | St. Jude Children's Research Hospital, Inc. | T-Cell Receptor for Treating Fibrolamellar Hepatocellular Carcinoma |
CN113092761A (zh) * | 2021-03-15 | 2021-07-09 | 成都益安博生物技术有限公司 | 一种弥漫大b细胞淋巴瘤的外周血tcr标志物及其检测试剂盒和应用 |
CN113109564A (zh) * | 2021-03-15 | 2021-07-13 | 成都益安博生物技术有限公司 | 一种急性髓细胞性白血病的外周血tcr标志物及其检测试剂盒和应用 |
CA3217738A1 (en) | 2021-05-05 | 2022-05-04 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4923799A (en) | 1984-02-06 | 1990-05-08 | The Ontario Cancer Institute | T cell specific cDNA clone |
US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
CA2116526A1 (en) | 1991-08-28 | 1993-03-18 | William V. Williams | T cell receptor-based therapy for rheumatoid arthritis |
US5364787A (en) | 1992-03-23 | 1994-11-15 | Idaho Research Foundation | Genes and enzymes involved in the microbial degradation of pentachlorophenol |
US20060134641A1 (en) * | 1992-05-22 | 2006-06-22 | Franklin Richard L | Treating viral infections with krill enzymes |
US5494794A (en) * | 1992-10-20 | 1996-02-27 | Emory University | Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease |
US5672509A (en) * | 1993-08-25 | 1997-09-30 | Pfizer Inc. | hPDE IV-C: a human phosphodiesterase IV isozyme |
CA2224970C (en) | 1996-04-16 | 2002-04-02 | Kishimoto, Tadamitsu | Method of detecting solid cancer cells and tissue atypia and method of testing tissues for use in bone marrow transplantation and peripheral blood stem cell transplantation |
US5942422A (en) * | 1996-11-14 | 1999-08-24 | The Trustees Of Columbia University In The City Of New York | Method for generating a directed, recombinant fusion nucleic acid |
GB9710820D0 (en) | 1997-05-27 | 1997-07-23 | Univ Dundee | Immunological method |
US6013444A (en) | 1997-09-18 | 2000-01-11 | Oligotrail, Llc | DNA bracketing locus compatible standards for electrophoresis |
AU5528198A (en) | 1997-12-03 | 1999-06-16 | Immune Response Corporation, The | Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides |
US6090593A (en) * | 1998-05-13 | 2000-07-18 | The United States Of America As Represented By The Secretary Of The Air Force | Isolation of expressed genes in microorganisms |
DK1066380T3 (da) | 1998-05-19 | 2002-01-28 | Avidex Ltd | Opløselig T-cellereceptor |
AU4932199A (en) | 1998-07-31 | 2000-02-21 | Haruo Sugiyama | Cancer antigens based on tumor suppressor gene wt1 product |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US20030072767A1 (en) | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
MXPA01003344A (es) | 1998-09-30 | 2004-04-21 | Corixa Corp | Composiciones y metodos para inmunoterapia especifica de wt1. |
GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
RU2251552C2 (ru) | 1999-02-23 | 2005-05-10 | Бейлор Колледж Оф Медисин | Vβ-Dβ-Jβ ОЛИГОНУКЛЕОТИД Т-КЛЕТОЧНОГО РЕЦЕПТОРА, ПАРА ПРАЙМЕРОВ, ОЛИГОНУКЛЕОТИДНЫЙ ЗОНД, СПОСОБ ОБНАРУЖЕНИЯ КЛОНА MBP83-99Vβ13.1 Т-КЛЕТОК, ЭКСПРЕССИРУЮЩИХ МОТИВ LGRAGLTY Т-КЛЕТОЧНОГО РЕЦЕПТОРА, НАБОР, СПОСОБ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ И СПОСОБ ЕГО МОНИТОРИНГА |
WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
US20040097703A1 (en) | 2001-03-22 | 2004-05-20 | Haruo Sugiyama | Wt1 modified peptide |
CA2451846A1 (en) | 2001-06-29 | 2003-01-09 | Chugai Seiyaku Kabushiki Kaisha | Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome |
EP1473564A4 (en) | 2001-09-18 | 2008-12-10 | Greenpeptide Co Ltd | METHOD OF DETECTING CELLULAR IMMUNITY AND ITS APPLICATION TO DRUGS |
US20050002951A1 (en) | 2001-09-28 | 2005-01-06 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
US8735357B2 (en) | 2001-09-28 | 2014-05-27 | International Institute Of Cancer Immunology, Inc. | Method of inducing antigen-specific T cells |
CN1688708A (zh) | 2002-01-09 | 2005-10-26 | 曼盛基因技术有限公司 | 检测t细胞增殖的基因序列方法 |
US7214492B1 (en) * | 2002-04-24 | 2007-05-08 | The University Of North Carolina At Greensboro | Nucleic acid arrays to monitor water and other ecosystems |
WO2003106682A1 (ja) | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Hla−a24拘束性癌抗原ペプチド |
US7342092B2 (en) | 2002-09-12 | 2008-03-11 | International Institute Of Cancer Immunology, Inc. | Cancer antigen peptide formulations |
WO2004063706A2 (en) * | 2003-01-08 | 2004-07-29 | Maxx Genetech Co., Ltd. | Method of detecting over-expression of t-cell receptor genes by real-time pcr |
EP2343083B1 (en) * | 2003-06-27 | 2014-01-15 | International Institute of Cancer Immunology, Inc. | Method of diagnosing cancer comprising the measurement of WT1-specific CTL precursor cells |
US20050191283A1 (en) * | 2003-10-16 | 2005-09-01 | Suzanne Kadereit | Methods of treating NFAT-related disorders |
US20080070835A1 (en) | 2003-11-05 | 2008-03-20 | International Institute Of Cancer Immunology, Inc | Hla-Dr-Binding Antigen Peptide Derived From Wt1 |
WO2005053603A2 (en) | 2003-12-08 | 2005-06-16 | Yeda Research And Development Co. Ltd. | Antigen receptor variable region typing |
US7576183B2 (en) * | 2003-12-24 | 2009-08-18 | Los Alamos National Security, Llc | Structure-based receptor MIMICS targeted against bacterial superantigen toxins |
DK1731605T3 (da) | 2004-03-31 | 2010-05-25 | Int Inst Cancer Immunology Inc | Cancerantigenpeptider der er afledt af WT1 |
GB0411771D0 (en) | 2004-05-26 | 2004-06-30 | Avidex Ltd | Nucleoproteins displaying native T cell receptor libraries |
US7674456B2 (en) * | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
GB0427585D0 (en) | 2004-12-16 | 2005-01-19 | Avidex Ltd | Assay |
WO2008026927A2 (en) | 2006-08-30 | 2008-03-06 | Academisch Medisch Centrum | Process for displaying t- and b-cell receptor repertoires |
JP2009278927A (ja) | 2008-05-23 | 2009-12-03 | Tohoku Univ | T細胞受容体を模倣する抗体断片及びその製造方法 |
CN105968191A (zh) | 2011-06-28 | 2016-09-28 | 株式会社癌免疫研究所 | 肽癌抗原-特异性t细胞的受体基因 |
-
2008
- 2008-02-28 KR KR1020097018554A patent/KR101669279B1/ko active IP Right Grant
- 2008-02-28 US US12/529,701 patent/US10093977B2/en not_active Expired - Fee Related
- 2008-02-28 BR BRPI0808341-0A2A patent/BRPI0808341A2/pt not_active Application Discontinuation
- 2008-02-28 KR KR1020157023123A patent/KR101773690B1/ko active IP Right Grant
- 2008-02-28 EP EP08720964A patent/EP2116596A4/en not_active Withdrawn
- 2008-02-28 WO PCT/JP2008/053469 patent/WO2008108257A1/ja active Application Filing
- 2008-02-28 MX MX2014010820A patent/MX343633B/es unknown
- 2008-02-28 EP EP19150097.4A patent/EP3492590A3/en not_active Withdrawn
- 2008-02-28 EP EP14192034.8A patent/EP2857508A3/en not_active Withdrawn
- 2008-02-28 EP EP16198218.6A patent/EP3173480A3/en not_active Withdrawn
- 2008-02-28 JP JP2009502541A patent/JP5808079B2/ja active Active
- 2008-02-28 KR KR1020177023678A patent/KR101900639B1/ko active IP Right Grant
- 2008-02-28 CN CN2008800134367A patent/CN101668853B/zh not_active Expired - Fee Related
- 2008-02-28 AU AU2008222061A patent/AU2008222061B2/en not_active Ceased
- 2008-02-28 MX MX2009009589A patent/MX2009009589A/es active IP Right Grant
- 2008-02-28 CN CN2013102585890A patent/CN103374576A/zh active Pending
- 2008-02-28 CA CA002679045A patent/CA2679045A1/en not_active Abandoned
- 2008-03-04 TW TW103145693A patent/TWI615470B/zh not_active IP Right Cessation
- 2008-03-04 TW TW097107430A patent/TWI615469B/zh not_active IP Right Cessation
-
2014
- 2014-02-20 US US14/184,979 patent/US10669584B2/en active Active
- 2014-02-20 US US14/184,816 patent/US20140315758A1/en not_active Abandoned
- 2014-03-20 JP JP2014058621A patent/JP5832572B2/ja active Active
-
2015
- 2015-07-30 JP JP2015151065A patent/JP6268129B2/ja active Active
-
2020
- 2020-04-23 US US16/857,005 patent/US20210017599A1/en not_active Abandoned
Non-Patent Citations (11)
Title |
---|
COULIE PG. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 98, 2001, pages 10290 - 10295 |
DIETRICH PY. ET AL., CANCER RES., vol. 61, 2001, pages 2047 - 2054 |
FARINA C. ET AL.: "Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens", INT. IMMUNOL., vol. 8, no. 9, 1996, pages 1463 - 1466, XP008115108 * |
GODELAINE D. ET AL., J. IMMUNOL., vol. 171, 2003, pages 4893 - 4897 |
KATO T. ET AL.: "Analysis of accumulated T cell clonotypes in patients with systemic lupus erythematosus", ARTHRITIS RHEUM., vol. 43, no. 12, 2000, pages 2712 - 2721, XP008115102 * |
MANDRUZZATO S. ET AL., J. IMMUNOL., vol. 169, 2002, pages 4017 - 4024 |
OKA Y. ET AL.: "Induction of WT1 (Wilm's tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression", PROC. NATL. ACAD. SCI. U.S.A., vol. 101, no. 38, 2004, pages 13885 - 13890, XP002391406 * |
OKA Y. ET AL.: "Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis", INT. J. HEMATOL., vol. 78, no. 1, 2003, pages 56 - 61, XP008115139 * |
O'KEFE C.L. ET AL.: "Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses", J. IMMUNOL., vol. 172, no. 3, 2004, pages 1960 - 1969, XP008115103 * |
See also references of EP2116596A4 |
VALMORI D. ET AL., J. IMMUNOL., vol. 168, 2002, pages 4231 - 4240 |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10500257B2 (en) | 2003-06-27 | 2019-12-10 | International Institute Of Cancer Immunology, Inc. | Method of selecting WT1 vaccine adaptive patient |
WO2009059804A2 (en) * | 2007-11-05 | 2009-05-14 | Medinnova As | T-cell receptor peptides specific for part of cd20, uses thereof, and methods of preparing cytotoxic t-cells |
WO2009059804A3 (en) * | 2007-11-05 | 2009-09-03 | Medinnova As | T-cell receptor peptides specific for part of cd20, uses thereof, and methods of preparing cytotoxic t-cells |
US9803246B2 (en) | 2011-06-28 | 2017-10-31 | International Institute Of Cancer Immunology, Inc. | Receptor gene for peptide cancer antigen-specific T cell |
US10648036B2 (en) | 2011-06-28 | 2020-05-12 | International Institute Of Cancer Immunology, Inc. | Receptor gene for peptide cancer antigen-specific T cell |
JPWO2013002086A1 (ja) * | 2011-06-28 | 2015-02-23 | 株式会社癌免疫研究所 | ペプチド癌抗原特異的t細胞のレセプター遺伝子 |
WO2013002086A1 (ja) | 2011-06-28 | 2013-01-03 | 株式会社癌免疫研究所 | ペプチド癌抗原特異的t細胞のレセプター遺伝子 |
EP3447140A2 (en) | 2011-06-28 | 2019-02-27 | International Institute of Cancer Immunology, Inc. | Receptor gene for peptide cancer antigen-specific t cell |
JP2017046698A (ja) * | 2011-06-28 | 2017-03-09 | 株式会社癌免疫研究所 | ペプチド癌抗原特異的t細胞のレセプター遺伝子 |
WO2014007266A1 (ja) * | 2012-07-02 | 2014-01-09 | 大日本住友製薬株式会社 | 癌抗原ペプチド経皮剤 |
JPWO2014007266A1 (ja) * | 2012-07-02 | 2016-06-02 | 大日本住友製薬株式会社 | 癌抗原ペプチド経皮剤 |
JPWO2014042226A1 (ja) * | 2012-09-12 | 2016-08-18 | 株式会社癌免疫研究所 | 抗原特異的ヘルパーt細胞レセプター遺伝子 |
JP2018143247A (ja) * | 2012-09-12 | 2018-09-20 | 株式会社癌免疫研究所 | 抗原特異的ヘルパーt細胞レセプター遺伝子 |
WO2014042226A1 (ja) * | 2012-09-12 | 2014-03-20 | 株式会社癌免疫研究所 | 抗原特異的ヘルパーt細胞レセプター遺伝子 |
US20160009781A1 (en) | 2012-09-12 | 2016-01-14 | International Institute Of Cancer Immunology, Inc. | Antigen-specific helper t-cell receptor genes |
US10815288B2 (en) | 2012-09-12 | 2020-10-27 | International Institute Of Cancer Immunology, Inc. | Antigen-specific helper T-cell receptor genes |
US11091531B2 (en) | 2012-09-12 | 2021-08-17 | International Institute Of Cancer Immunology, Inc. | Antigen-specific helper T-cell receptor genes |
JP2014143982A (ja) * | 2013-01-30 | 2014-08-14 | Igaku Seibutsugaku Kenkyusho:Kk | T細胞レセプターおよびその利用 |
US9663563B2 (en) | 2013-03-12 | 2017-05-30 | Sumitomo Dainippon Pharma Co., Ltd. | Aqueous liquid composition |
WO2020127357A1 (en) * | 2018-12-18 | 2020-06-25 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
CN113166228A (zh) * | 2018-12-18 | 2021-07-23 | 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 | 用于治疗b细胞恶性肿瘤的cd22特异性t细胞受体和过继性t细胞疗法 |
WO2021060343A1 (ja) * | 2019-09-24 | 2021-04-01 | オンコセラピー・サイエンス株式会社 | Urlc10由来ペプチドまたはdepdc1由来ペプチドを認識するヒトt細胞が発現するt細胞受容体 |
WO2021236548A1 (en) * | 2020-05-18 | 2021-11-25 | Board Of Regents, The University Of Texas System | Engineered t cell receptors and methods of use |
WO2022012280A1 (zh) * | 2020-07-11 | 2022-01-20 | 成都益安博生物技术有限公司 | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008108257A1 (ja) | 癌抗原特異的t細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用 | |
EP3447140A3 (en) | Receptor gene for peptide cancer antigen-specific t cell | |
NZ602119A (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
EP4282877A3 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
WO2008089053A3 (en) | Gp100-specific t cell receptors and related materials and methods of use | |
WO2011143624A3 (en) | Humanized and chimeric monoclonal antibodies to cd47 | |
WO2009042570A3 (en) | Modified t cell receptors and related materials and methods | |
WO2008105462A1 (ja) | ヘルパーt細胞の活性化方法およびそのための組成物 | |
WO2007113648A3 (en) | Ctla4 antibody combination therapy | |
WO2008061213A3 (en) | Genetic variations associated with tumors | |
WO2008011120A3 (en) | Human endogenous retrovirus polypeptide compositions and methods of use thereof | |
WO2009015284A8 (en) | Il-18 receptor antigen binding proteins | |
WO2008120998A3 (en) | Acoustically sensitive drug delivery particles | |
EP4269562A3 (en) | Antigen binding molecules and methods of use thereof | |
WO2008093280A3 (en) | Anti-idiotype monoclonal antibodies as mimotopes of the hiv gp120 antigen | |
WO2006047728A3 (en) | Bmp gene and fusion protein | |
WO2009030770A3 (en) | Methods and tools for prognosis of cancer in er- patients | |
WO2008112898A3 (en) | Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes | |
JP2015524788A5 (ja) | ||
BRPI0813743A2 (pt) | Método para produzir trombina humana recombinante, trombina recombinante, composição farmacêutica, sequência de dna isolada, vetor, sequência de aminoácido, e, célula hospedeira. | |
WO2009066462A1 (ja) | 細胞傷害性t細胞の誘導方法、細胞傷害性t細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン | |
WO2009049966A3 (en) | Methods and tools for prognosis of cancer in her2+ patients | |
WO2008070325A3 (en) | Genetic variations associated with tumors | |
JP2021502110A5 (ja) | ||
NO20084579L (no) | Fremgangsmate for vaksinering av individer som mottar immunmodulerende terapi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880013436.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08720964 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008222061 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2679045 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2008720964 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008720964 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5152/CHENP/2009 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2009502541 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097018554 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/009589 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008222061 Country of ref document: AU Date of ref document: 20080228 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12529701 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0808341 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090908 |